Aurora Cannabis’s Safari Flower Company received EU-GMP certification for its Niagara facility, strengthening its ability to export medical cannabis to regulated international markets. The European Union Good Manufacturing Practice approval covers the 59,000-square-foot cultivation and manufacturing site and is valid for three years.
Safari Flower Company is a wholly owned subsidiary of Aurora Cannabis Inc. (NASDAQ: ACB; TSX: ACB). Aurora acquired Safari in April 2026 specifically to add EU-GMP capacity to its global manufacturing network. Company statements identify Germany, Poland and the UK as immediate target markets for product supply from the Niagara facility.
EU-GMP certification requires documented quality systems, validated manufacturing processes and traceable supply chains. Regulators typically require EU-GMP for imported medical cannabis products; with this certification, Safari can ship into markets that enforce those standards without additional facility-level audits for the covered term. The three-year certificate indicates inspectors found the facility’s cultivation, processing and quality control systems meet the EU standard.
Brigitte Simons, CEO of Safari Flower Company, said the certification confirms the facility’s quality controls and enables the company to serve regulated supply chains. Company materials note the site has a history of prior EU-GMP accreditations and active export operations, implying an operational track record that supported the recent audit outcome.
The Niagara site’s 59,000 square feet include cultivation rooms and manufacturing areas used to produce dried flower and other medical-grade products that require strict environmental controls, batch records and tested potency and contaminant results. Aurora says the acquisition and certification are intended to align with its existing GMP-certified facilities in Canada and Germany and to provide incremental output for international medical demand.
Aurora lists multiple branded portfolios for medical markets, and adding Safari’s certified capacity aims to increase available supply for contracts in Europe and the UK. The company did not disclose projected annual output volumes from the Niagara facility in the announcement. However, the concrete effects of EU-GMP certification are clear: the site can be listed as a compliant supplier in procurement processes that require EU-GMP documentation and can fulfill export orders without interim facility qualification steps.
The news release also includes standard forward-looking cautions. Aurora notes that statements about future supply, market demand and financial results depend on assumptions such as stable production yields, access to capital, retention of key staff, and unchanged regulatory requirements. Risks that could alter outcomes include changes to import rules, shifts in market pricing, production disruptions, or difficulties integrating acquired operations.
Regulators and buyers in Germany, Poland and the UK typically require batch-level certificates of analysis, validated testing for potency and contaminants, and supply-chain traceability. EU-GMP certification addresses the manufacturing-site component of those requirements, but each export transaction will still need product-specific testing and permits under importing countries’ rules.
Industry observers view EU-GMP certification as a practical requirement for firms that want to supply tightly regulated medical markets. For Aurora, the certification provides documented compliance for a defined period and expands the company’s roster of GMP-certified production sites, which the company says supports contract fulfillment and long-term customer relationships in jurisdictions with strict import rules.
Aurora continues to operate other GMP facilities in Canada and Germany and lists its common shares on NASDAQ and the Toronto Stock Exchange under the symbol ACB. The company directs readers to its 2026 Annual Information Form for a detailed discussion of risk factors that could affect production, exports and financial results.
Key facts – Facility: Safari Flower Company, Niagara Region, Ontario – Size: 59,000 square feet – Certification: EU-GMP, three-year term – Acquisition: Purchased by Aurora in April 2026 – Target export markets cited: Germany, Poland, United Kingdom – Parent company tickers: NASDAQ: ACB; TSX: ACB
This certification allows Aurora to present the Niagara site as an EU-GMP-certified supplier when bidding for or fulfilling contracts that require that standard, and it reduces the need for duplicative site audits by importing authorities during the certificate term. Buyers will still require product-level testing and permits per local import rules before any shipment clears customs.
